CTOs on the Move

American Clinical Solutions

www.acslabtest.com

 
American Clinical Solutions is a leading provider of urine drug confirmation services, offering accurate testing for both prescription and illicit narcotics using the most advanced equipment available. Medical facilities and other healthcare providers rely on American Clinical to help ensure patient safety and maximize the benefits of prescription medicine use. ACS employs a unique, proprietary testing method with enhanced detection ability and improved accuracy which means physicians and other health care providers can prescribe with confidence. In addition to detecting improper use of prescribed and illicit drugs, ACS testing method helps healthcare providers monitor the efficacy of prescription regimens and ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

American Clinical Solutions raised $10M on 06/23/2015

Similar Companies

HASTINGS and PRINCE ED CNTY HLTH

HASTINGS and PRINCE ED CNTY HLTH is a Belleville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Academy of CME

American Academy of CME is a Skillman, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

P-B Health Home Care Agency

P-B Health Home Care Agency is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calibrate

Calibrate is a modern, medical metabolic health business changing the way the world treats weight.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.